New Detailed Data From Phase 3 Study Show Amgen's Repatha™ (Evolocumab) In Combination With Statins Reduced LDL-C By 67-76 Percent Compared To Placebo In Japanese Patients With High Cardiovascular Risk And High Cholesterol Read more about New Detailed Data From Phase 3 Study Show Amgen's Repatha™ (Evolocumab) In Combination With Statins Reduced LDL-C By 67-76 Percent Compared To Placebo In Japanese Patients With High Cardiovascular Risk And High Cholesterol
Amgen Announces 2015 Second Quarter Dividend Read more about Amgen Announces 2015 Second Quarter Dividend
Amgen Showcases Cardiovascular Pipeline At ACC.15 With New Cholesterol-Lowering And Chronic Heart Failure Data Read more about Amgen Showcases Cardiovascular Pipeline At ACC.15 With New Cholesterol-Lowering And Chronic Heart Failure Data
Amgen Announces Launch Of New Neulasta® (Pegfilgrastim) Delivery Kit Read more about Amgen Announces Launch Of New Neulasta® (Pegfilgrastim) Delivery Kit
Phase 3 Head-to-Head ENDEAVOR Study Demonstrates Superiority Of Kyprolis® (carfilzomib) Over Velcade® (bortezomib) In Patients With Relapsed Multiple Myeloma Read more about Phase 3 Head-to-Head ENDEAVOR Study Demonstrates Superiority Of Kyprolis® (carfilzomib) Over Velcade® (bortezomib) In Patients With Relapsed Multiple Myeloma
Amgen Receives Positive CHMP Opinion For Use Of Vectibix® (panitumumab) As First-Line Treatment In Combination With FOLFIRI Chemotherapy For Advanced Colorectal Cancer Read more about Amgen Receives Positive CHMP Opinion For Use Of Vectibix® (panitumumab) As First-Line Treatment In Combination With FOLFIRI Chemotherapy For Advanced Colorectal Cancer
Amgen Announces The European Medicines Agency Acceptance Of Kyprolis® (Carfilzomib) Marketing Authorization Application For The Treatment Of Relapsed Multiple Myeloma Read more about Amgen Announces The European Medicines Agency Acceptance Of Kyprolis® (Carfilzomib) Marketing Authorization Application For The Treatment Of Relapsed Multiple Myeloma
Amgen Announces Positive Results From Head-To-Head Study Comparing The Efficacy And Safety Of AMG 416 With Cinacalcet In Patients With Secondary Hyperparathyroidism Receiving Hemodialysis Read more about Amgen Announces Positive Results From Head-To-Head Study Comparing The Efficacy And Safety Of AMG 416 With Cinacalcet In Patients With Secondary Hyperparathyroidism Receiving Hemodialysis
Amgen To Present At The Cowen And Company 35th Annual Health Care Conference Read more about Amgen To Present At The Cowen And Company 35th Annual Health Care Conference
Amgen Announces FDA Advisory Committees To Review Talimogene Laherparepvec For The Treatment Of Patients With Metastatic Melanoma Read more about Amgen Announces FDA Advisory Committees To Review Talimogene Laherparepvec For The Treatment Of Patients With Metastatic Melanoma
